National Cancer Institute; Notice of Closed Meetings, 9735 [2015-03633]
Download as PDF
Federal Register / Vol. 80, No. 36 / Tuesday, February 24, 2015 / Notices
electronic applications to: https://
www.grants.gov.
Dated: February 10, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–03690 Filed 2–23–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
tkelley on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications/
contract proposals and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Centers of
Cancer Nanotechnology Excellence (CCNE).
Date: March 31–April 2, 2015
Time: 5:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: Bethesda North Marriott Hotel and
Conference Center; 5701 Marinelli Road;
North Bethesda, MD 20852.
Contact Person: Jeffrey E. DeClue, Ph.D.;
Scientific Review Officer; Research
Technology and Contract Review Branch;
Division of Extramural Activities; National
Cancer Institute; 9609 Medical Center Drive,
Room 7W238; Bethesda, MD 20892–9750;
240–276–6371; decluej@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Omnibus
R03 & R21 SEP–6.
Date: April 10, 2015.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove; 9609 Medical Center Drive, Room
7W030; Rockville, MD 20850; (Telephone
Conference Call).
Contact Person: Caron A. Lyman, Ph.D.
Chief, Scientific Review Officer; Research
Programs Review Branch; Division of
Extramural Activities; National Cancer
Institute, NIH; 9609 Medical Center Drive,
Room 7W126; Bethesda, MD 20892–9750;
240–276–6348; lymanc@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Molecular
VerDate Sep<11>2014
17:31 Feb 23, 2015
Jkt 235001
and Cellular Characterization of ScreenDetected Lesions.
Date: April 13, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center; 5701 Marinelli Road;
North Bethesda, MD 20852.
Contact Person: Caron A. Lyman, Ph.D.;
Chief, Scientific Review Officer; Research
Programs Review Branch; Division Of
Extramural Activities; National Cancer
Institute, NIH; 9609 Medical Center Drive,
Room 7W126; Bethesda, MD 20892–9750;
240–276–6348; lymanc@mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/sep/sep.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 18, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–03633 Filed 2–23–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke; Special
Emphasis Panel Clinical Trials SEP.
Date: March 5–6, 2015.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
9735
Place: Hotel Palomar, 2121 P Street NW.,
Washington, DC 20037.
Contact Person: Shanta Rajaram, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
NINDS/NIH/DHHS/Neuroscience Center,
6001 Executive Boulevard, Suite 3208, MSC
9529, Bethesda, MD 20892–9529, 301–435–
6033, rajarams@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: February 18, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–03638 Filed 2–23–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Small;
Business: Cancer Drug Development and
Therapeutics.
Date: March 16–17, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Lilia Topol, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6192,
MSC 7804, Bethesda, MD 20892, 301–451–
0131, ltopol@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Infectious Diseases and
Microbiology.
E:\FR\FM\24FEN1.SGM
24FEN1
Agencies
[Federal Register Volume 80, Number 36 (Tuesday, February 24, 2015)]
[Notices]
[Page 9735]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-03633]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications/contract proposals and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Centers of Cancer Nanotechnology Excellence (CCNE).
Date: March 31-April 2, 2015
Time: 5:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: Bethesda North Marriott Hotel and Conference Center; 5701
Marinelli Road; North Bethesda, MD 20852.
Contact Person: Jeffrey E. DeClue, Ph.D.; Scientific Review
Officer; Research Technology and Contract Review Branch; Division of
Extramural Activities; National Cancer Institute; 9609 Medical
Center Drive, Room 7W238; Bethesda, MD 20892-9750; 240-276-6371;
decluej@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Omnibus R03 & R21 SEP-6.
Date: April 10, 2015.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove; 9609 Medical
Center Drive, Room 7W030; Rockville, MD 20850; (Telephone Conference
Call).
Contact Person: Caron A. Lyman, Ph.D. Chief, Scientific Review
Officer; Research Programs Review Branch; Division of Extramural
Activities; National Cancer Institute, NIH; 9609 Medical Center
Drive, Room 7W126; Bethesda, MD 20892-9750; 240-276-6348;
lymanc@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Molecular and Cellular Characterization of Screen-Detected
Lesions.
Date: April 13, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda North Marriott Hotel & Conference Center; 5701
Marinelli Road; North Bethesda, MD 20852.
Contact Person: Caron A. Lyman, Ph.D.; Chief, Scientific Review
Officer; Research Programs Review Branch; Division Of Extramural
Activities; National Cancer Institute, NIH; 9609 Medical Center
Drive, Room 7W126; Bethesda, MD 20892-9750; 240-276-6348;
lymanc@mail.nih.gov.
Information is also available on the Institute's/Center's home
page: https://deainfo.nci.nih.gov/advisory/sep/sep.htm, where an
agenda and any additional information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: February 18, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-03633 Filed 2-23-15; 8:45 am]
BILLING CODE 4140-01-P